Both H&E and immunofluorescence stainings indicated reduced cell numbers in H358 and HCC827 tumor models after treatment with either ARS-1620 or gefitinib, independent of TGF-β1 (Figure 6A,C). Here, TGFB1 is linked to neoplasm.